Informal Report on the FDA’s Blood Safety Advisory Committee Meeting (July 26)

Patient advocate Heidi Dunlap Bauer attended the XMRV portion of the FDA’s Blood Safety Advisory Committee Meeting (July 26, 2010). She then wrote and shared an informal report on the proceedings – which can be found on the blogspot of the Blue Ribbon Campaign for ME/CFS.*

To read her report – “It’s All About the Prostate, Folks” – go to:

As Heidi comments:
“My general impression afterwards is that this was simply a show for the public, a nice safe production meant to dispel ‘public panic’ and focus almost solely on prostate cancer when XMRV was mentioned.”

The most interesting bit:
Is Heidi’s description of a presentation by Dr. Stuart Le Grice,  head of the National Cancer Institute’s HIV/AIDS & Cancer Virology Center of Excellence:

“He said their goal is to create a group of 6 assays (Viral, DNA, RNA, Western blot serological (antibodies) and immunihistochemistry) that they are completely satisfied with and then go head to head with other assays to compare.” Heidi indicates Le Grice, et al. appear to have found a way to detect XMRV in ‘spiked’ plasma and whole blood vs. control samples with 100% accuracy in a blinded analysis. “The name of the assay they use is Viral DERSE (der’-see),” she notes, and apparently this can produce findings in three days or less. “All I could say is, ‘Wow!'”

While you’re on the Blue Ribbon Campaign site – take a look at their clocks tracking:

• The days elapsed since the WPI published XMRV findings linking XMRV to ME/CFS

• The days elapsed waiting for publication of the NIH/FDA findings reportedly linking XMRV to ME/CFS.

Notice also that the site offers a link to sign a petition to release the NIH/FDA paper.


* The Blue Ribbon Campaign for ME/CFS ( is a nonprofit grassroots campaign to advocate for and raise awareness of ME/CFS worldwide.

1 Star2 Stars3 Stars4 Stars5 Stars (21 votes, average: 3.80 out of 5)

Leave a Reply